Learning Objectives:

  1. Review the current treatment options for immuno-oncology treatment of DLBCL
  2. Describe the evidence for PD-L1 gene locus amplifications as a marker for an inflamed microenvironment in DLCBL
  3. Compare the mutational and gene expression landscape of inflamed versus non-inflamed DLBCL, as well as the potential impact on future clinical trials
Session date: 
02/24/2020 - 12:00pm to 1:00pm CST
900 East 57th Street
KCBD Auditorium 1103
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Michael J. Leukam, MD, MS